Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company developing an orexin receptor 2 agonist for the treatment of narcolepsy and other sleep-wake disorders, announced third-quarter updates for the drug candidate, ORX750.
“Momentum continues to build with our orexin agonist development program,” says Saurabh Saha, MD, PhD, CEO of Centessa, in a release. “The preclinical data we recently shared at the World Sleep Congress show that ORX750 is a highly potent and selective novel orexin receptor 2 agonist that closely mimics the function of the endogenous peptide. We believe these data support a potential best-in-class profile for ORX750 for the treatment of narcolepsy and other sleep-wake disorders.”
Saha says in the release that the company is focused on rapidly moving ORX750 through Investigational New Drug (IND)-enabling studies, obtaining IND clearance, and initiating clinical development with the goal of sharing clinical proof of concept data in sleep-deprived healthy volunteers in 2024.
In addition, the company is exploring follow-up molecules for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.
In October, the Company announced a set of new preclinical data from in vivo and in vitro studies of its investigational, novel OX2R agonist, ORX750, that support a potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders. The preclinical data were presented recently at the World Sleep Congress and are also available in a recorded webcast.